Latest from Mayo Clinic Cancer Center

Alan H. Bryce, MD, discusses encouraging updates and emerging strategies in metastatic prostate cancer treatment.
Erik P. Castle, MD, discusses the role of cytoreductive nephrectomy in renal cell carcinoma based on interpretation of the CARMENA trial results.
Carlos E. Vargas, MD, discusses toxicities associated with stereotactic body radiation therapy compared with standard fractionated radiation therapy in prostate cancer. 
 
Thai H. Ho, MD, PhD, discusses frontline treatment considerations in metastatic renal cell carcinoma, the utility of TKI monotherapy, and new combinations on the horizon. 
Thai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma. 
Alan H. Bryce, MD, discusses how novel agents have impacted the nonmetastatic castration-resistant prostate cancer space.
Thai H. Ho, MD, PhD, discusses frontline treatment regimens in metastatic renal cell carcinoma.
OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.
Publication Bottom Border
Border Publication
x